Dr. Kurtz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Mayo Clinic College of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2010 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsA human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.Jenna M Kastenschmidt, Joseph G Schroers-Martin, Brian J Sworder, Suhas Sureshchandra, Michael S Khodadoust, Chih Long Liu, Mari Olsen, David M Kurtz, Maximilian Diehn...> ;Cell Stem Cell. 2024 Mar 7
- Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.Kathuria, K., Frank, M., Miklos, D., Alizadeh, A., Diehn, M., Shukla, N., Schroers-Martin, J., Sworder, B., Alig, S., Coutre, S., Roschewski, M., Khodadoust, M., Kurtz...> ;Blood Advances. 2024 Feb 13
- NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.Ehsan Tabari, Alexander F Lovejoy, Hai Lin, Christopher R Bolen, Seng Lor Saelee, Joshua P Lefkowitz, David M Kurtz, Alessia Bottos, Tina G Nielsen, Joana M Parreira, ...> ;Leukemia & Lymphoma. 2024 May 1
- Join now to see all
Abstracts/Posters
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCLDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Prev...David M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid MalignanciesDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin LymphomaDecember 13th, 2022- Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and ExpositionNovember 3rd, 2022
- Advances in Malignant Lymphoma: Discoveries from Precursors to ProgressionJune 20th, 2022
- Join now to see all
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
